These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33484864)

  • 1. Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia.
    Torres A; Garrity-Ryan L; Kirsch C; Steenbergen JN; Eckburg PB; Das AF; Curran M; Manley A; Tzanis E; McGovern PC
    Int J Infect Dis; 2021 Mar; 104():501-509. PubMed ID: 33484864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omadacycline for Community-Acquired Bacterial Pneumonia.
    Stets R; Popescu M; Gonong JR; Mitha I; Nseir W; Madej A; Kirsch C; Das AF; Garrity-Ryan L; Steenbergen JN; Manley A; Eckburg PB; Tzanis E; McGovern PC; Loh E
    N Engl J Med; 2019 Feb; 380(6):517-527. PubMed ID: 30726692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.
    Ramirez JA; Tzanis E; Curran M; Noble R; Chitra S; Manley A; Kirsch C; McGovern PC
    Clin Infect Dis; 2019 Aug; 69(Suppl 1):S33-S39. PubMed ID: 31367741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
    File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
    Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.
    Pai MP; Wilcox M; Chitra S; McGovern P
    Respir Med; 2021 Aug; 184():106442. PubMed ID: 34058682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
    Cornely OA; File TM; Garrity-Ryan L; Chitra S; Noble R; McGovern PC
    Int J Antimicrob Agents; 2021 Feb; 57(2):106263. PubMed ID: 33326848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
    Lodise TP; Mistry R; Young K; LaPensee K
    Clin Drug Investig; 2021 Mar; 41(3):269-275. PubMed ID: 33604769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study.
    Ramirez J; Deck DH; Eckburg PB; Curran M; Das AF; Kirsch C; Manley A; Tzanis E; McGovern PC
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab135. PubMed ID: 34160474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
    Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
    J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
    File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD
    Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
    File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
    BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
    Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
    Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
    O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
    Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omadacycline (Nuzyra)--a new tetracycline antibiotic.
    Med Lett Drugs Ther; 2019 May; 61(1572):74-77. PubMed ID: 31169800
    [No Abstract]   [Full Text] [Related]  

  • 16. Omadacycline: A New Tetracycline Antibiotic.
    Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
    Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
    Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral 5-Day Lefamulin for Outpatient Management of Community-Acquired Bacterial Pneumonia: Post-hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Trial.
    LoVecchio F; Schranz J; Alexander E; Mariano D; Meads A; Sandrock C; Moran GJ; Giordano PA
    J Emerg Med; 2021 Jun; 60(6):781-792. PubMed ID: 33731270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a
    Rodriguez GD; Warren N; Yashayev R; Chitra S; Amodio-Groton M; Wright K
    Front Med (Lausanne); 2023; 10():1225710. PubMed ID: 37575994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia.
    Tang HJ; Wang JH; Lai CC
    Medicine (Baltimore); 2020 Jul; 99(29):e21223. PubMed ID: 32702892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.